Tartaric Acid

Summary

Tartaric Acid (CHEMBL1236315) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 150.09 Da · C4H6O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1236315
Name	Tartaric Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	444305
ChEBI	CHEBI:15671
Molecular formula	C4H6O6
Molecular weight	150.09
InChIKey	FEWJPZIEWOKRBE-JCYAYHJZSA-N

SMILES: [C@@H]([C@H](C(=O)O)O)(C(=O)O)O

IUPAC name: (2R,3R)-2,3-dihydroxybutanedioic acid

ChEBI definition: The L-enantiomer of tartaric acid.

Also known as: E 334, E-334, FEMA NO. 3044, INS NO.334, INS-334, L-tartaric acid, NSC-62778, Tartaric acid, Tartaric acid component of baros, Tartrate, SID57264380, SID144210475

Patent coverage: 24,606 distinct patent families (56,091 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-lactamase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	6.2	Potency	631	nM	CHEMBL_ACT_4639133

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00822172	PHASE4	COMPLETED	Evaluation of Cilostazol in Combination With L-Carnitine
NCT07108777	PHASE2	RECRUITING	L-Carnitine Protective Effect in Nephrotoxicity
NCT01072812	PHASE1	TERMINATED	Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
NCT03439917	Not specified	COMPLETED	Effects of Carnitine Supplementation on Liver and Muscle

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).